Your session is about to expire
← Back to Search
Enzyme Replacement Therapy
ORGN001 (formerly ALXN1101) for Molybdenum Cofactor Deficiency
Phase 2
Waitlist Available
Research Sponsored by Origin Biosciences
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Male or female patients with a genetically confirmed diagnosis of MoCD Type A (MOCS1 mutation)
Currently treated with rcPMP infusions
Timeline
Screening 3 weeks
Treatment Varies
Follow Up baseline to month 24 for all patients plus additional follow-up to month 90
Awards & highlights
Study Summary
This trial will have three stages: a screening period, a 6-month treatment period, and a long-term extension period that is expected to last around 72 months.
Eligible Conditions
- Molybdenum Cofactor Deficiency
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ baseline to month 24 for all patients plus additional follow-up to month 90
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~baseline to month 24 for all patients plus additional follow-up to month 90
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Primary outcome measures
Safety of ORGN001 (Formerly ALXN1101)
Secondary outcome measures
Effect of ORGN001 (Formerly ALXN1101) on Neurologic Function Including Motor Examination
Long-term Safety of ORGN001 (Formerly ALXN1101)
Pharmacokinetics (Actual Plasma Concentration) of ORGN001 (Formerly ALXN1101)
+1 moreSide effects data
From 2022 Phase 2 & 3 trial • 5 Patients • NCT0262939340%
Vomiting
40%
Hypoglycaemia
40%
Hypocalcaemia
40%
Catheter site infection
20%
Device related infection
20%
Haematuria
20%
Bacteraemia
20%
Gastrointestinal viral
20%
Seizures
20%
Catheter site haemorrhage
20%
Gastroenteritis
20%
Bronchitis
20%
COVID-19
20%
Eczema
20%
Pathogen resistance
20%
Staphylococcus test positive
20%
Device related sepsis
20%
Conjunctival haemorrhage
20%
Hyperbilirubinaemia
20%
Seizure
20%
Viral infection
20%
Nasopharyngitis
20%
Catheter site swelling
20%
Pneumonia
20%
Anaemia
20%
Pyrexia
20%
Device leakage
20%
Tonsillitis
20%
Fall
20%
Conjunctivitis
20%
Central venous catheterisation
20%
Skin laceration
20%
Catheter site erythema
20%
Eye discharge
20%
Oral herpes
20%
Otitis media acute
20%
Cough
20%
Diarrhoea
20%
Cardiac failure
20%
Ventricular septal defect
20%
Respiratory syncytial virus infection
20%
Rhinorrhea
20%
Chiari network
20%
Anal fissure
20%
Catheter site rash
20%
Apneoa
20%
Dermatitis
20%
Complication associated with device
20%
Contusion
20%
Viral tonsillitis
100%
80%
60%
40%
20%
0%
Study treatment Arm
Patients Treated With ORGN001 (Formerly ALXN1101)
Trial Design
1Treatment groups
Experimental Treatment
Group I: ORGN001 (formerly ALXN1101)Experimental Treatment1 Intervention
daily IV infusions
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
ORGN001 (formerly ALXN1101)
2016
Completed Phase 3
~20
Find a Location
Who is running the clinical trial?
Origin BiosciencesLead Sponsor
4 Previous Clinical Trials
109 Total Patients Enrolled
Frequently Asked Questions
These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
Share this study with friends
Copy Link
Messenger